Sanofi Names New CEO
Successor to current CEO Olivier Brandicourt is announced.
Sanofi's Board of Directors have appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt, who is retiring. Hudson, 51, most recently Chief Executive Officer of Novartis, will take over on September 1.
Hudson, who will move to Paris for the role, has spent his 28-year career with major pharma companies. Serge Weinberg, Chairman of the Board of Directors of Sanofi, commented: "[Hudson's] skills and experience give him all the assets he needs to accelerate growth and lead the Group's adaptation to new strategic challenges, particularly in the areas of Research and Development and digital. His human values will enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world."
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
